300 related articles for article (PubMed ID: 32568573)
1. Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review.
Lunyera J; Mohottige D; Alexopoulos AS; Campbell H; Cameron CB; Sagalla N; Amrhein TJ; Crowley MJ; Dietch JR; Gordon AM; Kosinski AS; Cantrell S; Williams JW; Gierisch JM; Ear B; Goldstein KM
Ann Intern Med; 2020 Jul; 173(2):110-119. PubMed ID: 32568573
[TBL] [Abstract][Full Text] [Related]
2. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Woolen SA; Shankar PR; Gagnier JJ; MacEachern MP; Singer L; Davenport MS
JAMA Intern Med; 2020 Feb; 180(2):223-230. PubMed ID: 31816007
[TBL] [Abstract][Full Text] [Related]
3. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis.
Agarwal R; Brunelli SM; Williams K; Mitchell MD; Feldman HI; Umscheid CA
Nephrol Dial Transplant; 2009 Mar; 24(3):856-63. PubMed ID: 18952698
[TBL] [Abstract][Full Text] [Related]
4. An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis.
Zhang B; Liang L; Chen W; Liang C; Zhang S
PLoS One; 2015; 10(6):e0129720. PubMed ID: 26076348
[TBL] [Abstract][Full Text] [Related]
5. Adverse Events Associated with Intra-Arterial Administration of Gadolinium-Based Contrast Agents: A Systematic Review and Meta-Analysis.
MacLeod CA; Gauthier I; Davenport MS; McGrath TA; Khan F; Dos Santos MP; McInnes MDF; Schieda N
J Vasc Interv Radiol; 2023 Apr; 34(4):568-577.e10. PubMed ID: 36464013
[TBL] [Abstract][Full Text] [Related]
6. Current status of nephrogenic systemic fibrosis.
Daftari Besheli L; Aran S; Shaqdan K; Kay J; Abujudeh H
Clin Radiol; 2014 Jul; 69(7):661-8. PubMed ID: 24582176
[TBL] [Abstract][Full Text] [Related]
7. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents.
Penfield JG
Pediatr Nephrol; 2008 Dec; 23(12):2121-9. PubMed ID: 18543004
[TBL] [Abstract][Full Text] [Related]
8. GBCAs and Risk for Nephrogenic Systemic Fibrosis: A Literature Review.
Beam AS; Moore KG; Gillis SN; Ford KF; Gray T; Steinwinder AH; Graham A
Radiol Technol; 2017 Jul; 88(6):583-589. PubMed ID: 28900045
[TBL] [Abstract][Full Text] [Related]
9. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
[TBL] [Abstract][Full Text] [Related]
10. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure.
Bernstein EJ; Schmidt-Lauber C; Kay J
Best Pract Res Clin Rheumatol; 2012 Aug; 26(4):489-503. PubMed ID: 23040363
[TBL] [Abstract][Full Text] [Related]
11. Nephrogenic systemic fibrosis.
Weinreb JC; Kuo PH
Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
[TBL] [Abstract][Full Text] [Related]
12. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
[TBL] [Abstract][Full Text] [Related]
13. Nephrogenic systemic fibrosis and gadolinium-based contrast agents.
Abu-Alfa AK
Adv Chronic Kidney Dis; 2011 May; 18(3):188-98. PubMed ID: 21531325
[TBL] [Abstract][Full Text] [Related]
14. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents.
Smorodinsky E; Ansdell DS; Foster ZW; Mazhar SM; Cruite I; Wolfson T; Sugay SB; Iussich G; Shiehmorteza M; Kono Y; Kuo A; Sirlin CB
J Magn Reson Imaging; 2015 May; 41(5):1259-67. PubMed ID: 24811860
[TBL] [Abstract][Full Text] [Related]
15. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience.
Lemy AA; del Marmol V; Kolivras A; High WA; Matos C; Laporte M; Nortier JL
J Am Acad Dermatol; 2010 Sep; 63(3):389-99. PubMed ID: 20619488
[TBL] [Abstract][Full Text] [Related]
16. Gadolinium-Induced Fibrosis.
Todd DJ; Kay J
Annu Rev Med; 2016; 67():273-91. PubMed ID: 26768242
[TBL] [Abstract][Full Text] [Related]
17. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review.
Rudnick MR; Wahba IM; Leonberg-Yoo AK; Miskulin D; Litt HI
Am J Kidney Dis; 2021 Apr; 77(4):517-528. PubMed ID: 32861792
[TBL] [Abstract][Full Text] [Related]
18. [Nephrogenic systemic fibrosis: a rare disease with grave consequences].
Kielstein JT; Schiffer M
Internist (Berl); 2010 Jan; 51(1):39-44. PubMed ID: 20033388
[TBL] [Abstract][Full Text] [Related]
19. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
Weinreb JC; Abu-Alfa AK
J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
